These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23619944)

  • 1. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR
    Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
    Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
    PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
    Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
    Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
    Zhang W; Zhang W; Wang L; Zheng J; Xiao F
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
    PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
    Mascaux C; Wynes MW; Kato Y; Tran C; Asuncion BR; Zhao JM; Gustavson M; Ranger-Moore J; Gaire F; Matsubayashi J; Nagao T; Yoshida K; Ohira T; Ikeda N; Hirsch FR
    Clin Cancer Res; 2011 Dec; 17(24):7796-807. PubMed ID: 21994417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
    Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.